Key result
In a rat model of isoproterenol-induced kidney injury, ivabradine mitigated kidney fibrosis by decreasing type I collagen volume by 58% to 69% across glomerular, tubulointerstitial, and vascular sites.
Why the study?
To investigate whether chronic isoproterenol administration induces kidney alterations and whether ivabradine can attenuate potential kidney damage.
Does ivabradine reduce kidney fibrosis in an isoproterenol-induced kidney damage model in rats?
Does ivabradine reduce kidney fibrosis in an isoproterenol-induced kidney damage model in rats?
Ivabradine attenuates isoproterenol-induced kidney fibrosis in rats, suggesting potential renoprotective effects in models of cardiorenal syndrome.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for ivabradine renoprotection in catecholamine models; leaves open any human cardiorenal application.
This study investigated whether chronic isoproterenol administration could induce kidney alterations and whether ivabradine, a heart rate (HR)-reducing substance exerting cardiovascular protection, is able to attenuate potential kidney damage. Twenty-eight Wistar rats were divided into non-diseased controls, rats treated with ivabradine, rats treated with isoproterenol, and rats treated with isoproterenol plus ivabradine. Six weeks of isoproterenol administration was associated with decreased systolic blood pressure (SBP) (by 25%) and glomerular, tubulointerstitial and vascular/perivascular fibrosis due to enhanced type I collagen volume (7-, 8-, and 4-fold, respectively). Ivabradine reduced HR (by 15%), partly prevented SBP decline (by 10%) and site-specifically mitigated kidney fibrosis by decreasing type I collagen volume in all three sites investigated (by 69, 58, and 67%, respectively) and the ratio of type I collagen-to-type III collagen in glomerular and vascular/perivascular sites (by 79 and 73%, respectively). We conclude that ivabradine exerts protection against kidney remodelling in isoproterenol-induced kidney damage.
No takes yet. Share an insight, caveat, or question.
Baka et al. (2023) studied Isoproterenol-induced kidney injury (n=28). Ivabradine vs. Isoproterenol alone was evaluated on Volume of type I collagen in intraglomerular sites (69% reduction, p=<0.0001). In a rat model of isoproterenol-induced kidney injury, ivabradine mitigated kidney fibrosis by decreasing type I collagen volume by 58% to 69% across glomerular, tubulointerstitial, and vascular sites.
Synapse has enriched 10 related papers. Consider them for comparative context: